Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Hereditary lobular breast cancer with an emphasis on E-cadherin genetic defect.

Corso G, Figueiredo J, La Vecchia C, Veronesi P, Pravettoni G, Macis D, Karam R, Lo Gullo R, Provenzano E, Toesca A, Mazzocco K, Carneiro F, Seruca R, Melo S, Schmitt F, Roviello F, De Scalzi AM, Intra M, Feroce I, De Camilli E, Villardita MG, Trentin C, De Lorenzi F, Bonanni B, Galimberti V.

J Med Genet. 2018 Jul;55(7):431-441. doi: 10.1136/jmedgenet-2018-105337. Epub 2018 Jun 21.

PMID:
29929997
2.

The Italian Ministry of Health promotes more than 300 research projects to improve cancer prevention, treatment, and prognosis.

Corso G, Macis D, Veronesi P, Bonanni B, Galimberti V.

Eur J Cancer Prev. 2018 May;27(3):287-288. doi: 10.1097/CEJ.0000000000000443. No abstract available.

PMID:
29570106
3.

A Presurgical Study of Lecithin Formulation of Green Tea Extract in Women with Early Breast Cancer.

Lazzeroni M, Guerrieri-Gonzaga A, Gandini S, Johansson H, Serrano D, Cazzaniga M, Aristarco V, Macis D, Mora S, Caldarella P, Pagani G, Pruneri G, Riva A, Petrangolini G, Morazzoni P, DeCensi A, Bonanni B.

Cancer Prev Res (Phila). 2017 Jun;10(6):363-370. doi: 10.1158/1940-6207.CAPR-16-0298. Epub 2017 Apr 11.

4.

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial.

Johansson H, Gray KP, Pagani O, Regan MM, Viale G, Aristarco V, Macis D, Puccio A, Roux S, Maibach R, Colleoni M, Rabaglio M, Price KN, Coates AS, Gelber RD, Goldhirsch A, Kammler R, Bonanni B, Walley BA; the TEXT principal investigators.

Breast Cancer Res. 2016 Nov 8;18(1):110.

5.

A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.

Johansson H, Gandini S, Serrano D, Gjerde J, Lattanzi M, Macis D, Guerrieri-Gonzaga A, Aristarco V, Mellgren G, Lien E, DeCensi A, Bonanni B.

Breast Cancer Res Treat. 2016 Aug;159(1):97-108. doi: 10.1007/s10549-016-3932-7. Epub 2016 Aug 2.

PMID:
27484880
6.

A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer Patients.

Aristarco V, Serrano D, Gandini S, Johansson H, Macis D, Guerrieri-Gonzaga A, Lazzeroni M, Feroce I, Pruneri G, Pagani G, Toesca A, Caldarella P, DeCensi A, Bonanni B.

Cancer Prev Res (Phila). 2016 May;9(5):349-56. doi: 10.1158/1940-6207.CAPR-15-0311. Epub 2016 Feb 29.

7.

Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.

DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, Pruneri G, Serrano D, Schwab M, Hofmann U, Mora S, Aristarco V, Macis D, Bassi F, Luini A, Lazzeroni M, Bonanni B, Pollak MN.

Breast Cancer Res Treat. 2014 Nov;148(1):81-90. doi: 10.1007/s10549-014-3141-1. Epub 2014 Sep 25.

8.

Circulating adiponectin and breast cancer risk: a systematic review and meta-analysis.

Macis D, Guerrieri-Gonzaga A, Gandini S.

Int J Epidemiol. 2014 Aug;43(4):1226-36. doi: 10.1093/ije/dyu088. Epub 2014 Apr 15. Review.

9.

Circulating hormones and breast cancer risk in premenopausal women: a randomized trial of low-dose tamoxifen and fenretinide.

Johansson H, Bonanni B, Gandini S, Guerrieri-Gonzaga A, Cazzaniga M, Serrano D, Macis D, Puccio A, Sandri MT, Gulisano M, Formelli F, Decensi A.

Breast Cancer Res Treat. 2013 Dec;142(3):569-78. doi: 10.1007/s10549-013-2768-7. Epub 2013 Nov 17.

PMID:
24241787
10.

A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer.

Serrano D, Lazzeroni M, Gandini S, Macis D, Johansson H, Gjerde J, Lien E, Feroce I, Pruneri G, Sandri M, Bassi F, Brenelli F, Luini A, Cazzaniga M, Varricchio C, Guerrieri-Gonzaga A, DeCensi A, Bonanni B.

Breast Cancer Res. 2013 Jun 20;15(3):R47. doi: 10.1186/bcr3439.

11.

Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer.

Macis D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Magni P, Ruscica M, Lazzeroni M, Serrano D, Cazzaniga M, Mora S, Feroce I, Pizzamiglio M, Sandri MT, Gulisano M, Bonanni B, Decensi A.

J Clin Oncol. 2012 Jan 10;30(2):151-7. doi: 10.1200/JCO.2011.35.2237. Epub 2011 Dec 12.

12.

Lapatinib activity in premalignant lesions and HER-2-positive cancer of the breast in a randomized, placebo-controlled presurgical trial.

Decensi A, Puntoni M, Pruneri G, Guerrieri-Gonzaga A, Lazzeroni M, Serrano D, Macis D, Johansson H, Pala O, Luini A, Veronesi P, Galimberti V, Dotti MC, Viale G, Bonanni B.

Cancer Prev Res (Phila). 2011 Aug;4(8):1181-9. doi: 10.1158/1940-6207.CAPR-10-0337. Epub 2011 Jun 17.

13.

Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial.

Serrano D, Lazzeroni M, Zambon CF, Macis D, Maisonneuve P, Johansson H, Guerrieri-Gonzaga A, Plebani M, Basso D, Gjerde J, Mellgren G, Rotmensz N, Decensi A, Bonanni B.

Pharmacogenomics J. 2011 Apr;11(2):100-7. doi: 10.1038/tpj.2010.17. Epub 2010 Mar 23.

PMID:
20309015
14.

Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia.

Bonanni B, Serrano D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Macis D, Cazzaniga M, Luini A, Cassano E, Oldani S, Lien EA, Pelosi G, Decensi A.

Clin Cancer Res. 2009 Nov 15;15(22):7053-60. doi: 10.1158/1078-0432.CCR-09-1354. Epub 2009 Nov 3.

15.

Role of traditional and new biomarkers in breast carcinogenesis.

Macis D, Cazzaniga M, De Censi A, Bonanni B.

Ecancermedicalscience. 2009;3:157. doi: 10.3332/ecancer.2009.157. Epub 2009 Oct 29.

16.

Analysis of the presence of cutaneous and mucosal papillomavirus types in ductal lavage fluid, milk and colostrum to evaluate its role in breast carcinogenesis.

Cazzaniga M, Gheit T, Casadio C, Khan N, Macis D, Valenti F, Miller MJ, Sylla BS, Akiba S, Bonanni B, Decensi A, Veronesi U, Tommasino M.

Breast Cancer Res Treat. 2009 Apr;114(3):599-605. doi: 10.1007/s10549-008-0040-3. Epub 2008 May 9.

PMID:
18465220
17.

The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial.

Lazzeroni M, Macis D, Decensi A, Gandini S, Sandri MT, Serrano D, Guerrieri-Gonzaga A, Johansson H, Mora S, Daldoss C, Omodei U, Bonanni B.

Ecancermedicalscience. 2008;2:67. doi: 10.3332/ecancer.2008.67. Epub 2008 Feb 6.

18.

Randomized dose-ranging trial of tamoxifen at low doses in hormone replacement therapy users.

Decensi A, Gandini S, Serrano D, Cazzaniga M, Pizzamiglio M, Maffini F, Pelosi G, Daldoss C, Omodei U, Johansson H, Macis D, Lazzeroni M, Penotti M, Sironi L, Moroni S, Bianco V, Rondanina G, Gjerde J, Guerrieri-Gonzaga A, Bonanni B.

J Clin Oncol. 2007 Sep 20;25(27):4201-9. Epub 2007 Aug 20.

PMID:
17709798
19.

Methylenetetrahydrofolate reductase (MTHFR) and breast cancer risk: a nested-case-control study and a pooled meta-analysis.

Macis D, Maisonneuve P, Johansson H, Bonanni B, Botteri E, Iodice S, Santillo B, Penco S, Gucciardo G, D'Aiuto G, Rosselli Del Turco M, Amadori M, Costa A, Decensi A.

Breast Cancer Res Treat. 2007 Dec;106(2):263-71. Epub 2007 Jan 27.

PMID:
17260091
20.

Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial.

Bonanni B, Macis D, Maisonneuve P, Johansson HA, Gucciardo G, Oliviero P, Travaglini R, Muraca MG, Rotmensz N, Veronesi U, Decensi AU.

J Clin Oncol. 2006 Aug 1;24(22):3708-9; author reply 3709. No abstract available.

PMID:
16877740
21.

Factors involved in vivo and in vitro maturation of canine oocytes.

Luvoni GC, Chigioni S, Allievi E, Macis D.

Theriogenology. 2005 Jan 1;63(1):41-59. Review.

PMID:
15589272
22.

Factors associated with circulating levels of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in 740 women at risk for breast cancer.

Johansson H, Baglietto L, Guerrieri-Gonzaga A, Bonanni B, Mariette F, Macis D, Serrano D, Sandri MT, Decensi A.

Breast Cancer Res Treat. 2004 Nov;88(1):63-73.

PMID:
15538047
23.

Meiosis resumption of canine oocytes cultured in the isolated oviduct.

Luvoni GC, Chigioni S, Allievi E, Macis D.

Reprod Domest Anim. 2003 Oct;38(5):410-4.

PMID:
12950695
24.

Jagged-1 mutation analysis in Italian Alagille syndrome patients.

Pilia G, Uda M, Macis D, Frau F, Crisponi L, Balli F, Barbera C, Colombo C, Frediani T, Gatti R, Iorio R, Marazzi MG, Marcellini M, Musumeci S, Nebbia G, Vajro P, Ruffa G, Zancan L, Cao A, DeVirgilis S.

Hum Mutat. 1999;14(5):394-400.

PMID:
10533065
25.

The distribution of DR4 haplotypes in Sardinia suggests a primary association of type I diabetes with DRB1 and DQB1 loci.

Cucca F, Lampis R, Frau F, Macis D, Angius E, Masile P, Chessa M, Frongia P, Silvetti M, Cao A, De Virgiliis S, Congia M.

Hum Immunol. 1995 Aug;43(4):301-8.

PMID:
7499178
26.

HLA-DQB1*0305 and -DQB1*0304 alleles among Sardinians. Evolutionary and practical implications for oligotyping.

Cucca F, Frau F, Lampis R, Floris M, Argiolas L, Macis D, Cao A, De Virgiliis S, Congia M.

Hum Immunol. 1994 Jun;40(2):143-9.

PMID:
7928445

Supplemental Content

Support Center